Cabergoline/lanreotide Reactions 1680, p76 - 2 Dec 2017 Telogen effluvium: case report A 49-year-old woman developed telogen effluvium during treatment with lanreotide and cabergoline [routes and outcome not stated; not all dosages stated]. The woman, who had a history of acromegaly, was started on lanreotide autogel 120mg every 56 days. She also had a nd history of pituitary adenoma. Four days after the 2 dose of lanreotide, she observed a progressive diffuse scalp hair loss. All other causes of alopecia were ruled out. Her examination showed a non-scarring diffuse hair loss affecting the scalp globally, suggestive of telogen effluvium. Eventually, the intensity of hair loss increased. The woman also experienced psychological disturbances related to her new appearance. Therefore, lanreotide treatment was discontinued. Five months after the discontinuation of lanreotide, hair loss improved significantly. Later, she was started on cabergoline in increasing doses due to active acromegaly and showed a slow decrease in insulin- like growth factor-1 (IGF-1) and growth hormone levels. Eighteen months after the initiation of cabergoline, a complete biochemical response was achieved. However, hair loss reoccurred coinciding with the increase in cabergoline dose and was not as severe as in case of lanreotide treatment. Author comment: "Scalp hair loss is an underreported adverse event of somatostatin analogs therapy that in severe cases may require treatment withdrawal." We cannot rule out a direct effect of Lanreotide, because with cabergoline, we also observed a normalization of IGF-1 levels, and the degree of alopecia that the patient referred was not as severe as with Lanreotide." Alvarez-Escola C, et al. Severe scalp hair loss in a female patient with acromegaly treated with lanreotide autogel after unsuccessful surgery. Clinical Case Reports 3: 945-948, No. 11, Nov 2015. Available from: URL: - Spain 803284474 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial